ArticleHarm reduction journal2025
'I won't make it without this program': the impact of safer opioid supply program closures in Ontario.
Article in Harm reduction journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A continuum of disconnection: the impacts of safer supply program closures on continuity of care, transition, and total loss of service access.Harm reduction journal · 2026Article
- Safe Supply at Insite, North America's First Supervised Consumption Site: A Case Report of Reduced Harms From the Toxic Drug Supply in a Client Prescribed Powdered Fentanyl Alternative.Drug and alcohol review · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCanada is in the midst of a worsening overdose crisis, driven largely by the unregulated drug supply. In response, safer opioid supply (SOS) programs were implemented to provide pharmaceutical-grade opioids alongside critical services. However, in August 2024, Ontario's provincial government introduced restrictions on harm reduction initiatives, coinciding with the expiration of federal funding, forcing many programs to close. In their place, the government announced the implementation of Homelessness and Addiction Recovery Treatment Hubs, which exclude harm reduction programs, including SOS programs. This study explores the experiences of SOS program clients and the anticipated impacts of these program closures on their lives.
methodsA qualitative study design was used, involving semi-structured interviews with people who use drugs who were enrolled in six SOS programs across Ontario. Participants were recruited through convenience and snowball sampling. Eligible participants were current SOS clients (≥ 6 months), aged 18 or older, and English-speaking. Interviews were conducted virtually and explored participants' experiences with SOS programs, anticipated impacts of program closures, and strategies to mitigate risks. Data were thematically analyzed using NVivo.
resultsParticipants reported that SOS programs reduced their reliance on the unregulated drug supply, decreased their overdose risk, and connected them to wraparound services. The impending closures triggered widespread fear, uncertainty, and anxiety, particularly about returning to the unregulated supply. Participants also expressed concerns over the loss of access to critical health and social services and the potential decline in their quality of life. Many expressed frustration over the lack of meaningful alternatives, difficulties in securing new prescribers, and distress over forced medication tapers.
conclusionThis study highlights participants' concerns that SOS program closures may force them back into an increasingly dangerous unregulated market, ultimately putting their lives at risk, along with reversing the many benefits SOS programs provided, such as connections to essential health and social services. By replacing harm reduction programs with treatment services, the government is not reducing the demand for opioid use; instead, it forces a return to the unregulated drug market, ultimately putting individuals at risk of overdose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.